Zilong Hao1, Ming Liu, Zhiqin Liu, Donghao Lv. 1. Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan Province, China, 610041.
Abstract
BACKGROUND: Huperzine A, a form of herbal medicine, has been considered as an alternative treatment for vascular dementia (VaD) in China. OBJECTIVES: To assess the efficacy and safety of Huperzine A in patients with vascular dementia. SEARCH STRATEGY: The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG) was searched on 7 July 2008 using the terms: huperzi* OR ayapin OR scoparon*. The CDCIG Specialized Register contains records from all major health care databases (The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources. The review authors searched the following databases in August 2008 using the terms 'Huperzine A', 'Shishanjianjia', 'Haboyin' and 'Shuangyiping': The Chinese Biomedical Database (CBM) (1977 to August 2008); Chinese Science and Technique Journals Database (VIP) (1989 to August 2008); China National Knowledge Infrastructure (CNKI) (1979 to August 2008); The Chinese Clinical Trials Register (ChiCTR, August 2008); Google (August 2008). In addition, the review authors searched reference lists, relevant clinical trials and contacted researchers in an effort to identify further published and unpublished studies. SELECTION CRITERIA: Randomized controlled trials comparing Huperzine A with placebo in patients with vascular dementia were considered eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials for inclusion, assessed trial quality, and extracted data. MAIN RESULTS: Only one small trial, involving 14 participants, was included. No significant beneficial effect of Huperzine A on the improvement of cognitive function measured by MMSE for VaD (WMD 2.40; 95% CI -4.78 to 9.58) was observed. No death from all causes at the end of treatment were reported. At present, other outcome measures were not available in any of the trials. Although no statistically significant differences were found between the Huperzine A-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms. AUTHORS' CONCLUSIONS: There is no [convincing] evidence that Huperzine A is of value in vascular dementia based on one small trial. It deserves further research.
BACKGROUND:Huperzine A, a form of herbal medicine, has been considered as an alternative treatment for vascular dementia (VaD) in China. OBJECTIVES: To assess the efficacy and safety of Huperzine A in patients with vascular dementia. SEARCH STRATEGY: The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG) was searched on 7 July 2008 using the terms: huperzi* OR ayapin OR scoparon*. The CDCIG Specialized Register contains records from all major health care databases (The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many trials databases and grey literature sources. The review authors searched the following databases in August 2008 using the terms 'Huperzine A', 'Shishanjianjia', 'Haboyin' and 'Shuangyiping': The Chinese Biomedical Database (CBM) (1977 to August 2008); Chinese Science and Technique Journals Database (VIP) (1989 to August 2008); China National Knowledge Infrastructure (CNKI) (1979 to August 2008); The Chinese Clinical Trials Register (ChiCTR, August 2008); Google (August 2008). In addition, the review authors searched reference lists, relevant clinical trials and contacted researchers in an effort to identify further published and unpublished studies. SELECTION CRITERIA: Randomized controlled trials comparing Huperzine A with placebo in patients with vascular dementia were considered eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials for inclusion, assessed trial quality, and extracted data. MAIN RESULTS: Only one small trial, involving 14 participants, was included. No significant beneficial effect of Huperzine A on the improvement of cognitive function measured by MMSE for VaD (WMD 2.40; 95% CI -4.78 to 9.58) was observed. No death from all causes at the end of treatment were reported. At present, other outcome measures were not available in any of the trials. Although no statistically significant differences were found between the Huperzine A-treated and control groups, the confidence intervals for the treatment effect estimates were wide and included both clinically significant benefits and clinically significant harms. AUTHORS' CONCLUSIONS: There is no [convincing] evidence that Huperzine A is of value in vascular dementia based on one small trial. It deserves further research.
Authors: Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri Journal: Stroke Date: 2011-07-21 Impact factor: 7.914
Authors: Daniel J Cuthbertson; Sean R Johnson; Jasenka Piljac-Žegarac; Julia Kappel; Sarah Schäfer; Matthias Wüst; Raymond E B Ketchum; Rodney B Croteau; Joaquim V Marques; Laurence B Davin; Norman G Lewis; Megan Rolf; Toni M Kutchan; D Doel Soejarto; B Markus Lange Journal: Phytochemistry Date: 2013-04-16 Impact factor: 4.072
Authors: Mei Feng; Jingmin Lu; Brian H May; Shaonan Liu; Xinfeng Guo; Anthony Lin Zhang; Charlie Changli Xue; Chuanjian Lu Journal: BMJ Open Date: 2016-03-25 Impact factor: 2.692